Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Biogen Inc.    BIIB

BIOGEN INC.

(BIIB)
  Report
Delayed Quote. Delayed Nasdaq - 01/25 04:00:00 pm
275.54 USD   +2.26%
01/25VERICEL : Appoints Joe Mara Chief Financial Officer
MT
01/24SUN TECHNO OVERSEAS : Gets Approval to Change Name
MT
01/22PRESS RELEASE : BB BIOTECH AG: Vaccines leading -2-
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion

01/22/2018 | 10:55am EST
FILE PHOTO: A logo is seen in front of the entrance at the headquarters of French drugmaker Sanofi in Paris

PARIS (Reuters) - French healthcare group Sanofi (>> Sanofi) has agreed to buy U.S. haemophilia specialist Bioverativ (>> Bioverativ Inc) for $11.6 billion(8.34 billion pounds), its biggest deal for seven years and a major play to strengthen its presence in treatments for rare diseases.

PARIS (Reuters) - French healthcare group Sanofi (>> Sanofi) has agreed to buy U.S. haemophilia specialist Bioverativ (>> Bioverativ Inc) for $11.6 billion(8.34 billion pounds), its biggest deal for seven years and a major play to strengthen its presence in treatments for rare diseases.

Several analysts said the deal looked expensive, given uncertainties in the haemophilia market due to the arrival of new drug treatments, and Sanofi shares fell 4 percent on Monday, the worst performance on France's benchmark CAC-40 index.

The move comes at a time of renewed interest by large drugmakers in smaller biotech firms, with Celgene (>> Celgene Corporation) also announcing a $9 billion deal to buy Juno Therapeutics (>> Juno Therapeutics Inc), and predictions by some experts that 2018 will see a substantial pick-up in mergers and acquisitions.

Sanofi has agreed to buy all of the outstanding shares of Bioverativ for $105 apiece in cash, a premium of 64 percent to Bioverativ's closing price on January 19.

Bioverativ, a maker of haemophilia drugs, was separated from Biogen Inc (>> Biogen) early last year. Its shares surged to $104 in early U.S. trading.

The agreed transaction marks Sanofi's successful return to deal-making after its failure to land major takeovers in recent years. It is its biggest acquisition since the 2011 takeover of U.S. biotech company Genzyme for around $20 billion.

Sanofi lost out on buying California-based cancer specialist Medivation to Pfizer (>> Pfizer) in 2016, and also missed acquiring Swiss biotech company Actelion, which was bought by Johnson & Johnson (>> Johnson & Johnson) last year.

"With Bioverativ, we welcome a leader in the growing haemophilia market," Sanofi Chief Executive Olivier Brandicourt said.

The market dealing with treatments for haemophilia is an important one that is evolving rapidly as a new drug from Roche (>> Roche Holding Ltd.) changes the landscape and gene therapy holds out the promise of a possible one-time cure.

Sanofi said the sector had around $10 billion in annual sales, with 181,000 people affected worldwide, and haemophilia represented the largest market for rare diseases, set to grow by more than 7 percent per year through to 2022.

MORE DEALS?

Sanofi expects the acquisition, which brings it established haemophilia products Eloctate and Alprolix, to be immediately accretive to its business earnings per share in the full 2018 financial year and up to 5 percent accretive for the following year.

However, some analysts questioned the cost.

"Bioverativ looks a relatively expensive acquisition. It is logical in terms of building around Sanofi's presence and pipeline in rare diseases and haemophilia, though management may have to argue against concerns on competition," Jefferies analysts wrote in a note to clients.

"The obvious parallel is Shire's (>> Shire) highly unpopular acquisition of Baxalta; but Sanofi's 2011 acquisition of rare disease specialist Genzyme was also unpopular at the time, yet has it turned into a major success story," Kepler analysts said.

Sanofi added it would fund the takeover with a mixture of existing cash resources and a debt issue.

"We have the means to make further takeovers," added Brandicourt on a conference call, without going into further details.

Brandicourt has said in the past he was ready to do deals of a similar size to the $20 billion purchase of Genzyme to help accelerate growth at France's biggest drugmaker. One asset analysts and bankers believe could be of interest is Pfizer's consumer health unit, although competition for this business is likely to be fierce.

Sanofi said it expected to achieve a return on its invested capital (ROIC) in excess of the cost of capital within three years. The French group also expects to preserve its strong credit rating.

This month Celgene (>> Celgene Corporation) agreed to pay up to $7 billion to take over Impact Biomedicines.

In Europe, Novo Nordisk (>> Novo Nordisk A/S) has offered $3.1 billion for Ablynx (>> Ablynx) and Japan's Takeda Pharmaceutical (>> Takeda Pharmaceutical Co Ltd) plans to buy TiGenix (>> TiGenix NV) for $630 million.

The spate of deal-making follows a relatively subdued 2017 for biotech M&A.

Lazard (>> Lazard Ltd) advised Sanofi on the deal, while Guggenheim Securities and J.P. Morgan (>> JP Morgan Chase & Company) advised Bioverativ.

(Additional reporting by Ben Hirschler in London, Laurence Frost and Matthias Blamont in Paris, and Shubham Kalia in Bengaluru; Editing by Keith Weir and Mark Potter)

By Sudip Kar-Gupta


© Reuters 2018
Stocks mentioned in the article
ChangeLast1st jan.
BIOGEN INC. 2.26% 275.54 Delayed Quote.12.53%
CELGENE 0.10% 108.24 End-of-day quote.68.89%
JOHNSON & JOHNSON 1.49% 165.98 Delayed Quote.5.46%
JPMORGAN CHASE & CO. -1.25% 132.12 Delayed Quote.5.29%
JUST GROUP PLC -1.25% 74.506 Delayed Quote.7.94%
LAND CO., LTD. 12.50% 9 End-of-day quote.12.50%
LAZARD LTD -1.66% 42.72 Delayed Quote.0.99%
NOVO NORDISK A/S 0.58% 452.05 Delayed Quote.5.39%
PFIZER INC. 2.00% 37.28 Delayed Quote.1.28%
ROCHE HOLDING AG 1.11% 324.35 Delayed Quote.3.82%
SANOFI -0.04% 81.59 Real-time Quote.3.56%
SWISS RE LTD 0.55% 80.5 Delayed Quote.-3.94%
TAKEDA PHARMACEUTICAL COMPANY LIMITED 3.54% 3714 End-of-day quote.-1.09%
All news about BIOGEN INC.
01/25VERICEL : Appoints Joe Mara Chief Financial Officer
MT
01/24SUN TECHNO OVERSEAS : Gets Approval to Change Name
MT
01/22PRESS RELEASE : BB BIOTECH AG: Vaccines leading -2-
DJ
01/19BIOGEN : Morgan Stanley Adjusts Biogen PT to $352 From $357, Maintains Overweigh..
MT
01/14BIOGEN : Aducanumab data review and Q&A with Alzheimer's Disease International
PU
01/13BIOGEN : to Report Fourth Quarter and Full Year 2020 Financial Results February ..
PU
01/13DENALI THERAPEUTICS : Strategic Outlook, Upcoming Data for DNL310 Warrant Price ..
MT
01/13BIOGEN : A statement about Biogen Political Action Committee
PU
01/12DEADLINE TODAY : The Schall Law Firm Announces the Filing of a Class Action Laws..
PR
01/11EISAI : Lilly Alzheimer's drug slows mental, functional decline in mid-stage tri..
RE
More news
Financials (USD)
Sales 2020 13 391 M - -
Net income 2020 4 276 M - -
Net Debt 2020 2 814 M - -
P/E ratio 2020 10,4x
Yield 2020 -
Capitalization 42 401 M 42 401 M -
EV / Sales 2020 3,38x
EV / Sales 2021 3,76x
Nbr of Employees 7 400
Free-Float 86,1%
Chart BIOGEN INC.
Duration : Period :
Biogen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOGEN INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 33
Average target price 294,79 $
Last Close Price 275,54 $
Spread / Highest target 63,3%
Spread / Average Target 6,98%
Spread / Lowest Target -36,5%
EPS Revisions
Managers and Directors
NameTitle
Michel Vounatsos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Michael R. McDonnell Chief Financial Officer & Executive Vice President
Alfred W. Sandrock Chief Medical Officer & EVP-Research & Development
Mark Hernon Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN INC.12.53%42 401
CSL LIMITED-2.70%96 486
SAMSUNG BIOLOGICS CO.,LTD.-4.36%47 370
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.12.91%41 235
ALEXION PHARMACEUTICALS, INC.2.23%35 304
CELLTRION HEALTHCARE CO LTD--.--%21 154